Web 990x483 pharma soci
Jul 16, 2019

Blue Prism Drives Innovation and Modernization Across Pharmaceutical and Life Sciences Industries

Twitter Twitter Twitter Twitter

Automation Initiatives at Celgene, Merck, Pfizer and Pharmaceutical Product Development (PPD) Accelerate Digital Transformations for Improved Patient Outcomes

LONDON, AUSTIN TX – July 16, 2019 — Leading companies in the life sciences and pharmaceutical industries such as Celgene, Merck KGaA, Pfizer, and Pharmaceutical Product Development (PPD) are turning to Blue Prism (AIM: PRSM), a global leader in Robotic Process Automation (RPA), to expand modernization and digitally transform. In industries struggling to keep up with the rapid pace of innovation, using Blue Prism’s connected-RPA platform has helped these companies automate processes, improve speed to delivery and liberate resources. This enables these organizations to then drive faster drug discovery, improve clinical trial efficacy and ensure regulatory compliance.

The drug discovery process in pharmaceutical companies is prohibitively lengthy and data-intensive, with millions of molecules in data libraries and clinical trial duration increasing to an average of 6.8 years[1]. As drug development costs soar to a cost of $2.6 billion[2] for a prescription drug that gets FDA approval, pharmaceutical companies are under pressure to streamline workflows, reduce expenses and improve margins.

The deployment of Blue Prism’s connected-RPA platform has enabled dozens of world leading life sciences and pharmaceutical development organizations to optimize clinical and operational effectiveness, which empower care teams and employees – while engaging patients and customers. To integrate data and improve manual processes, Celgene Fusion worked with Blue Prism, Appian, and Princeton Blue to build GIGi, the company’s first digital worker. Since GIGi’s launch, Celgene has automated processes that ensure tools and data are in the right hands at the right time and have resulted in decreased cycle times from five days to less than one day.

Pfizer uses connected-RPA to automate a wide range of processes including supporting the production of its clinical study reports. For example, automations around the creation of report visualizations now reduce human error and save the team an estimated 10,000 hours annually. While RPA is often associated with back-office Shared Service, since January 2018, Pfizer has deployed over 47 automations within core operations outside of Global Business Services (GBS). Connected-RPA has been applied to key processes that include FDA compliance, product labelling updates and reconciling shipment documentation.

“The biotech industry faces increased pressure to bring blockbuster treatments to market while somehow lowering prices and outpacing generic patent challenges. In parallel, the number of clinical studies is increasing at a rate 4 – 5x headcount, a frenzy of M&A activities leads to more fragmented systems, all while regulatory bodies consistently move the goal posts,” says Josh Noble, Director of Life Sciences for Blue Prism. “We’re seeing significant customer growth in the application of intelligent automation for safety, R&D, and clinical operations, which enhance workflows and efficiencies, freeing staff to focus on patient-centric services and improved outcomes. Our customers like Covance and PPD are achieving not just bottom-line benefits, but also creating opportunities to differentiate their market offerings and customer experience.”

Another example of how automation can digitally transform was discussed in a recent Blue Prism Café, when James Sheehy, Director of Business Transformation and Projects at Gilead Sciences indicated that, “We could not ignore robotics or intelligent process automation. As a team we wanted to explore if there was value in the application of robotics – that’s when our RPA journey began. So, the key task was building a scalable Digital Workforce to tackle transactional activities and liberate human capacity for other value-add activities.”

Blue Prism’s Digital Workforce supports the workplace with an agile solution that helps companies automate and scale business processes. From appointment setting to patient registration, employee HR services, and clinical trial management, Blue Prism enables secure data collection to make healthcare more efficient, patient centric, and more agile than ever before. For more information on Blue Prism’s solutions for health and life sciences, visit: https://www.blueprism.com/solutions/industry/health-life-sciences.

[1] DiMasi JA, Grabowski HG, Hansen RW. Innovation in the Pharmaceutical Industry: New Estimates of R&D Costs. Journal of Health Economics. 2016; 47:20-33

[2] DiMasi JA, Grabowski HG, Hansen RW. Innovation in the Pharmaceutical Industry: New Estimates of R&D Costs. Journal of Health Economics. 2016; 47:20-33

About Blue Prism

Media Contact

The Latest From Blue Prism


ANZ Automation Partner Showcase with Accenture Avanade

You’re invited to join us on Thursday, August 13 at 11am AEST for the Blue Prism Automation Partner Showcase with Accenture and Avanade.

Register Now
Intelligent Automation 2025 Banner

Intelligent Automation 2025 – The Cyborg Enterprise

Welcome to 2025, where the most successful global enterprises have seamlessly augmented humans with digital workers.

Read More
Thumbnail showing the skyline of a city
Case Studies

Siam Commercial Bank Returns 100,000 Hours Back to the Business with Intelligent Automation

Siam Commercial Bank wins 2020 APAC All-Star award for driving value across their intelligent automation program.

Read More

Automation you can bank on…

Intelligent automation is grown-up, governed, enterprise-ready, people-first automation that’s smart, secure, scalable and way more successful than desktop task-bots.

©2020 Blue Prism Limited. “Blue Prism”, the “Blue Prism” logo and Prism device are either trademarks or registered trademarks of Blue Prism Limited and its affiliates. All Rights Reserved.”